Skip to main content

Table 1 Participant clinical features

From: Change in exhaled nitric oxide during peanut challenge is related to severity of reaction

Clinical feature Entire cohort (n = 36)
Age (years)
 Median (min, max) 10.2 (5.1, 17.1)
Gender (%)
 Males 22 (61)
Previous peanut ingestion (%)
 Total 28 (78)
Previous adrenaline usage (%)
 Total 1 (3)
Other food allergy (%)
 Total 7 (19)
Household smokers (%)
 Total 7 (19)
Allergic rhinitis (%)
 Total 26 (72)
AR severity for those with AR-max = 4a
 Median (min, max) 2 (1, 4)
Eczema ever (%)
 Total 29 (81)
Eczema active treatment (%)
 Total 8 (22)
SCORAD for those with visible eczema
 Median (min, max) 14.7 (6.0, 36.0)
Asthma ever (%)
 Total 15 (42)
Current preventer (%)
 Total 8 (22)
Current reliever (%)
 Total 10 (28)
Exercise related wheeze or dry nocturnal cough (%)b
 Total 16 (44)
No allergy in challenge (%)
 Total 15 (42)
CANA in challenge (%)
 Total 12 (33)
Anaphylaxis in challenge (%)
 Total 9 (25)
Peanut SPT (mm)
 Median (min, max) 5.8 (0, 10.0)
Peanut sIgE (kU/L)
 Median (min, max) 1.35 (0.01, 92.00)
Ara h2 sIgE (kU/L)
 Median (min, max) 0.85 (0.00, 70.30)
FeNO (NIOX VEROc) (ppb)
 Median (min, max) 23 (5, 97)
Percent predicted FEV1d
 Median (min, max) 102 (72, 124)
Percent predicted FVCd
 Median (min, max) 100 (70, 128)
Percent predicted FEV1/FVCd
 Median (min, max) 100 (82, 114)
  1. AR allergic rhinitis, SCORAD SCORing Atopic Dermatitis SPT skin prick test, sIgE specific immunoglobulin E, FeNO fraction exhaled nitric oxide, p.p.b Parts per billion. FEV1 forced expiratory volume in 1 s, FVC forced vital capacity
  2. a AR severity: 1 = intermittent mild, 2 = intermittent mod-severe, 3 = persistent mild, 4 = persistent mod-severe
  3. b Exercise related wheeze or dry nocturnal cough, not related to respiratory infection in the previous 12 months
  4. c Only 33 patients were able to have FeNO measured via NIOX VERO
  5. d Only 21 patients were able to have spirometry performed